JAMES PATRINELY to Cohort Studies
This is a "connection" page, showing publications JAMES PATRINELY has written about Cohort Studies.
Connection Strength
0.203
-
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 05 01; 7(5):744-748.
Score: 0.097
-
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA Netw Open. 2023 08 01; 6(8):e2327145.
Score: 0.028
-
Coworker Reports about Unprofessional Behavior in Plastic Surgery. Plast Reconstr Surg. 2023 04 01; 151(4):901-907.
Score: 0.027
-
Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy. JAMA Dermatol. 2022 06 01; 158(6):661-669.
Score: 0.026
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 06; 22(6):836-847.
Score: 0.024